The development of lentiviral vectors that use Rev-independent mechanisms of nuclear export for their genomic RNA could facilitate the construction of novel anti-HIV vectors. We have improved the titers of Rev-independent lentiviral vectors having the SRV-1 CTE by mutating the major splice donor and acceptor sites present in the vector and by relocalization of the CTE sequences adjacent to the HIV-1 Keywords: Rev-independent; lentiviral vector; CTE; gene therapy; HIV/AIDS The use of HIV-based conditionally replicating vectors expressing anti-HIV genes for the treatment of AIDS has several theoretical advantages over the current vector systems being employed.
The use of HIV-based conditionally replicating vectors expressing anti-HIV genes for the treatment of AIDS has several theoretical advantages over the current vector systems being employed. 1 Even in the absence of specific inhibitory genes, these vectors would be able to inhibit HIV replication by acting as decoys for the HIV regulatory proteins Tat and Rev, and by competing for packaging into HIV-1-encoded virions, facilitating the spread of the vector to unprotected cells in vivo. [2] [3] [4] [5] In order to provide the most effective inhibition of HIV replication, the vector must have a competitive advantage for packaging over the wild-type virus mRNA. To achieve this when an anti-HIV gene is inserted into the vector, the vector must be less sensitive to the anti-HIV gene than wildtype virus.
Some of the most potent anti-HIV genes characterized so far are transdominant negative mutants of Rev. 6, 7 Expressing such anti-HIV genes in HIV-based vectors would require the use of a Rev-independent system to produce significant quantities of vector. Several attempts have been made to develop Rev-independent lentiviral vectors based on HIV-1 or SIV-1. [8] [9] [10] [11] [12] [13] These systems make use of the MPMV or SRV-1 constitutive transport element (CTE) to complement for the absence of the RRE/Rev mRNA transport mechanism. Most studies have focused on the use of the CTE to increase the expression of Gag/Pol from helper plasmids lacking RRE sequences, while using transfer vectors that are dependent on the RRE/Rev mRNA transport mechanism. In these cases the synthesis of Gag/Pol was reduced seven-fold, 8 to 50-fold 9 relative to those using the RRE/Rev regulatory mechanism, resulting in vector titers that were 10 4 and 10 cfu/ml, respectively. In the best reported case, titers of 10 5 cfu/ml have been obtained using an analogous combination vector system. 10 In a previous report, we explored the reciprocal combination system, in which the RRE sequences in the transfer vector were replaced by the SRV-1 CTE while using a fully Rev-dependent helper vector.
14 It has been argued that the presence of the RRE in the transfer vector rather that in the helper vector would increase the safety of the vector as recombinantion events occurring during packaging would produce transfer vectors retaining the RRE that would be incompetent for replication in the absence of Rev. However, in conditionally replicating lentiviral vectors designed to express TdRev, the Rev-independent character of the vector has to reside in the transfer vector itself rather than in the helper vector. This report's goal was to design the most optimal CTE + Rev-independent lentiviral vector.
An example of a fully Rev-dependent vector is pcCG6 (Figure 1 ). This vector contains an RRE element cloned within an intron, expresses EGFP under the control of the CMV promoter and can produce biologically active titers in excess of 10 6 cfu/ml. 14 Cotransfection of this plasmid with the Rev-dependent helper pCMV⌬R8.2 15 produces vector preparations capable of transducing 27% of the target cells ( Figure 2a ). As we previously reported, replacing the RRE sequences by a 280-bp fragment containing the SRV-1 CTE (vector pcCG8), results in a 15-fold reduction in vector titers (Figure 2a , P Ͻ 0.001). This was consistent with the reduction in vector titers observed by others when introducing the CTE in one of the components of the packaging system. As the function of the CTE is to increase the transport of unspliced cytoplasmic mRNAs by facilitating their nuclear export rather than by preventing their splicing, 16 we reasoned that we might be able to increase vector titers by augmenting the fraction of unspliced cytoplasmic mRNA available for packaging. This was accomplished by mutating the major splice donor and acceptor sites that were flanking the CTE, creating vector pcCG9 14 which showed a six-fold increase in the number of transduced cells with respect to pcCG8 (Figure 2a , P Ͻ 0.01). In spite of this improvement, vector titers were approximately 7 × 10 5 cfu/ml, which was still five-fold lower than a fully Rev-dependent vector system. It has been reported that the MPMV CTE functions in a position-dependent manner in the context of replicationincompetent SIV-1 vectors. 17 These experiments indicated that the function of CTE decreases as the distance between the CTE and the poly(A) sequences increases beyond 200 bp. As the distance between the CTE and the poly(A) site in the 3ЈHIV LTR in our vector pcCG8 and pcCG9 is 2390 bp, we tested whether moving the CTE closer to the poly(A) site would improve vector titers. To do this we removed the fragment containing the CTE sequences from pcCG8 and pcCG9 and cloned it downstream of the EGFP gene to create vectors pcCG8-3C and pcCG9-3C (Figure 1 ). This reduced the distance between the CTE and the poly(A) site to 730 nt. Figure 2a shows that the percentage of GFP + cells that can be obtained with these vectors in parallel transfection and transduction assays is 12-fold (P Ͻ 0.01) and three-fold (P Ͻ 0.01) higher for pcCG8-3C and pcCG9-3C than for pcCG8 and pcCG9, respectively. This suggests that moving the CTE to a location closer to the poly(A) site was more beneficial to improve vector function than mutating the splicing signals. Moreover, the combination of these two modifications has an additive effect, allowing the increase of titers to levels greater than observed with a fully Revdependent vector system such as pcCG6 (1.6-fold; P Ͻ 0.02). 
For vectors containing the EGFP marker gene (a), 1 ml of undiluted supernatant was used for the transductions, and cells were analyzed by FACS 36 h after transduction. For cells having the Neo marker gene (b), 1:10 serial dilutions of the filtered supernatant were used to transduce TE671 cells, which were selected in DMEM supplemented with G418 1 mg/ml for 12-14 days. Bars represent the averages and standard deviations for five values (a) or seven values (b), respectively.
We next swiched the CMV-EGFP expression cassette for an SV40-Neo expression cassette in pcCG9-3C, as this marker permits quantification of the colony-forming units present in the vector supernatant. This created vector pcSN9-3C (Figure 1) . We compared the vector titers of pcSN9-3C with the previously described vectors pcSN6 and pcSN9 that have the same SV40-Neo expression cassette.
14 Moving the CTE closer to the 3Ј HIV LTR produces a 17-fold increase in vector titers (Figure 2b , P Ͻ 0.01). These titers (1.4 × 10 6 cfu/ml) are very close to the titers that can be obtained with a fully Rev-dependent vector such as pcSN6 (1.8 × 10 6 cfu/ml). In order to make a direct comparison of the vector titer Improved RRE − /CTE + lentiviral vectors MR Mautino et al differences between pcSN6, pcSN9 and pcSN9-3C we performed a packaging competition experiment by a two-vector cotransfection (Figure 3 ). The resultant supernatant was used to transduce target cells from which specific DNA fragments were amplified by PCR from their genomic DNA. The relative intensity of the signals amplified from each vector sequence gives an estimation of the relative input titers that can be obtained with each vector (in the same transfection and transduction events). The data suggest that vector pcSN9-3C is packaged and transduced with an efficiency that has about nine-fold higher than the fully Rev-dependent vector pcSN6, and 18-fold higher than vector pcSN9. An interesting observation is that in these two-vector competition experiments the overall titer on TE671 cells was not affected with respect to what is observed when transfecting one vector at a time (not shown). This suggests that Gene Therapy the presence of heterozygous virions does not reduce the overall functionality of the vector preparations.
We then asked whether the efficiency of particle formation was affected by this modification. To assess this, we purified virion mRNA from equal aliquots of vector supernatant and measured the amount of DNAse-treated vector RNA by dot blot hybridization with a probe complementary to the HIV LTR (Figure 4a ). Control for absence of DNA contamination was performed by measuring the elimination of a reporter plasmid that was added to the supernatant before starting the viral RNA purification. Quantification of the hybridization signals indicates that the viral RNA levels of pcSN9-3C are twofold the levels seen for the Rev-dependent vector pcSN6, and six-fold the levels of RNA observed for pcSN9. When these values were normalized for the total number of capsids measured as p24 present in the supernatant, the results indicate that vector pcSN9-3C has a higher packaging efficiency than vector pcSN6 (1.4-fold) or pcSN9 (five-fold) (Figure 4b ). This might reflect higher levels of unspliced genomic RNA available for packaging, either as a result of an enhanced nuclear export efficiency or an enhanced vector genomic RNA stability.
In summary, we have improved the titers of Rev-independent CTE-based lentiviral transfer vectors by mutating the splicing signals and locating the CTE elements closer to the 3Ј end of the vector transcript, and by packaging them with an HIV-1 helper that uses the RRE/Rev regulatory mechanism to drive the expression of Gag/Pol. The titers obtained with this combination packaging system are of the same level or even higher than the titer that can be obtained with a fully Rev-dependent packaging system. Here, the transfer and helper genomes share homology only in the truncated gag region that forms part of the packaging signal of the transfer vector (468 nt) and thus they should be less prone to generate replication competent vectors than packaging systems in which both the helper and transfer vectors share homology in the RRE region. Moreover, this system gives approximately 15-fold higher titers than the best reciprocal combination packaging system in which the CTE is used to increase expression of Gag/Pol from the helper plasmid and the transfer vector retains the RRE/Rev regulatory elements.
A lentiviral vector whose genomic mRNA does not require Rev for transport to the cytoplasm would possess a competitive advantage for packaging with respect to the genomic RNA of wild-type HIV-1 in cells where TdRev is being expressed by the vector. Such TdRevexpressing lentiviral vectors may be an extremely potent anti-HIV gene therapy system.
